Anderson Heiji Lima Miyazaki

Anderson Heiji Lima Miyazaki

Auto-generated profile, based on publicly available information

Anderson Heiji Lima Miyazaki

GASEO Medicina Ocupacional, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Revista Latino-Americana de Enfermagem
Verified
Journal Article
Open access
PDF file
JMJordana Carvalhaes de Moraes
Jordana Carvalhaes de Moraes
Fernanda Daniela Dornelas NunesFernanda Daniela Dornelas Nunes
Fernanda Daniela Dornelas Nunes
FCFernanda Borchers Coeli-Lacchini
Fernanda Borchers Coeli-Lacchini
AMAnderson Heiji Lima Miyazaki
Anderson Heiji Lima Miyazaki
MFMilena Flória-Santos
Milena Flória-Santos
Riccardo LacchiniRiccardo Lacchini
Riccardo Lacchini
Objective: to verify the existence of elements that justify the use of pharmacogenetics by the Brazilian nurse. Method: this is a quantitative, cross-sectional, observational, descriptive study, whose final sample was 67 individuals. The participants were healthy at the time of the study and reported a history of previous use and the occurrence of adverse effects by drugs commonly used and metabolized by CYP2C9. We collected 4 mL of venous blood for subsequent DNA extraction by salting out method and genotyping of the CYP2C9*2 and CYP2C9*3 polymorphisms, using Polymerase Chain Reaction in real time using Taqman assays. Results: the use of drugs metabolized by CYP2C9 was frequent (more than 75% of the individuals have already used between 2 or 4 of these drugs). Regarding adverse events, there were 19 perceived symptomatic occurrences associated with drugs metabolized by CYP2C9. The allele frequency of the polymorphism * 2 and * 3 in the population studied was 11.1% and 7.5%, respectively, and there was a coincidence between the presence of alleles of low enzyme activity and the occurrence of adverse effects. Conclusion: there are elements that justify the adoption of pharmacogenetics in the nursing care to reduce the occurrence of adverse reactions to drugs metabolized by CYP2C9.